Muscles, fats and simple blood test can predict menopausal women's health
It is also practical and cheaper than current methods of measuring muscle, such as the current gold standard magnetic resonance imaging scans or strength tests, which are also more time-consuming.
This new insight from a longitudinal cohort study of midlife women in Singapore shone light on how muscle strength, visceral fat and their association with physical decline after menopause can potentially lead to downstream health impacts among women here.
Researchers from the National University Hospital (NUH) and National University of Singapore (NUS) found that women with a lower creatinine-to-cystatin C ratio (CCR) – a marker derived from blood tests – had less muscle and walked more slowly as they age.
Creatinine is a by-product of normal muscle function and energy use, and a higher level indicates higher skeletal muscle mass or poor kidney function.
Cystatin C is a protein produced by the body's cells that is filtered out by the kidneys. A normal cystatin C level rules out poor kidney function.
A low CCR of under 8.16 was associated with a lower muscle volume of 0.35 litres in the thigh, and a slower gait of 0.049m a second.
This suggested that CCR could be a useful early warning sign for age-related muscle loss, which may lead to falls, frailty and reduced quality of life.
The findings were published in Menopause, a monthly peer-reviewed journal, in March.
The scientists involved in the study are from the Integrated Women's Health Programme (IWHP) at NUH and the NUS Yong Loo Lin School of Medicine.
The IWHP was initiated to identify and address the healthcare needs of midlife Singaporean women. It recruited a cohort of 1,200 Chinese, Malay and Indian women aged 45 to 69 between 2014 and 2016 – about 70 per cent of whom were post-menopausal. Their health metrics were then tracked over time.
In the first study based on this cohort, published in international journal Maturitas in October 2023, the researchers shared a ranking of menopausal symptoms – with joint and muscular discomfort found to be the most reported symptom among women in Singapore.
Called arthralgia, it had moderate or severe impact on a third of the midlife women of the cohort.
A subsequent study, published in the Diabetes, Obesity and Metabolism journal in October 2024, found that women with both weak muscle strength and high levels of visceral fat – the deep belly fat around the internal organs – had the highest risk of developing prediabetes or type 2 diabetes.
Their risk was 2.63 times higher than that of women who had normal muscle strength and lower fat levels.
Having just one of these conditions also increased their risk, though to a lesser degree. The risk from having high visceral fat alone is 1.78 times higher. Among those with weak muscle strength, women with high visceral fat faced 2.84 times as much risk compared with those with low visceral fat.
Explaining the impetus for the study, IWHP lead Yong Eu Leong said: 'Muscle... burns up fat. What about those who have weak muscles? Does it affect the risk for diabetes in the future?'
The cohort's initial muscle and visceral fat measurements served as a baseline for researchers to track changes over the years.
Researchers then analysed how changes in fat and muscle measurements taken about six years later – by then, about 90 per cent of the women were post-menopausal – related to whether women had developed diabetes.
Professor Yong, who also heads the division of benign gynaecology in the Department of Obstetrics and Gynaecology at NUH, noted that a large proportion of women in Singapore are 'skinny fat', where their body mass index is within the normal range, but that they have high levels of visceral fat and low muscle mass.
'One way (to know what your risks are) is to measure your walk and the speed at which you walk. If you cannot walk fast and straight, then your health is not so good. We wanted to see if we can develop a test that can predict gait speed. We wanted to look at molecules that actually measure muscle functions,' he said.
'These findings validated our previous (IWHP) research that showed that women should not just focus on weight loss, but on building muscle strength through exercise for diabetes prevention,' Prof Yong said.
One participant of the IWHP, administrative assistant Sabarina Jumarudin, is living proof of the findings.
The 59-year-old grandmother used to weigh 93kg and suffered from sleep apnoea.
Since undergoing bariatric surgery at NUH in 2018, a procedure that modifies the digestive system to help people with obesity lose weight, she has lost more than 30kg.
Mindful of keeping her weight down, Madam Sabarina walks to the MRT station every day instead of taking the shuttle service, and takes the stairs instead of the escalator to catch the train.
'On my way home, I usually take a longer route to ensure I clock at least 10,000 steps a day, and practise stretching and breathing exercises to strengthen my core,' she said.
'I realised that small but consistent changes do make a big impact on my health, so I do what I can on a daily basis, and it gives me confidence to not only stay healthy physically and mentally but also stave off diabetes,' she added.
Source: The Straits Times © SPH Media Limited. Permission required for reproduction
Discover how to enjoy other premium articles here
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
6 minutes ago
- CBS News
RFK Jr.'s plans for preventive health panel spark "deep concerns" from medical association
The American Medical Association is expressing "deep concern" after a report that Health and Human Services Secretary Robert F. Kennedy may be planning to remove all members of the U.S. Preventive Services Task Force. The task force, also known as the USPSTF, is a panel of independent medical experts whose recommendations help guide insurance companies and doctors' decisions about a range of preventive health measures, like cancer and diabetes screenings as well as HIV and cholesterol drugs. In a letter posted on Sunday, the AMA — the largest association of physicians in the U.S. — addressed Kennedy over a report published Friday in The Wall Street Journal. The WSJ story cited sources familiar with the matter as saying Kennedy plans to dismiss the task force members because he views them as too "woke." "USPSTF plays a critical, non-partisan role in guiding physicians' efforts to prevent disease and improve the health of patients by helping to ensure access to evidence-based clinical preventive services," the AMA's letter said. "As such, we urge you to retain the previously appointed members of the USPSTF and commit to the long-standing process of regular meetings to ensure their important work can continue without interruption." In a statement to CBS News Friday, an HHS spokesperson said, "No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again." on how the USPSTF can better support HHS' mandate to Make America Healthy Again." The task force was created more than 40 years ago, but its work took on added significance after passage of the Affordable Care Act in 2010. The law requires health insurers and group health plans to provide preventive services that are recommended by the task force without imposing co-pays, deductibles or other cost-sharing charges on patients. In June, the U.S. Supreme Court upheld the structure of the task force, but ruled that its members are "inferior officers" that can be "removable at will" by the HHS secretary. As the case played out, nonprofit organizations warned the Supreme Court that eliminating cost-sharing for services like breast cancer screenings or HIV-prevention medications would dissuade patients from seeking medical care. Last month, Kennedy fired all 17 members of the Advisory Committee for Immunization Practice, also known as ACIP, a separate government panel of that makes vaccine recommendations. He later named eight new advisers, including several allies he has worked with closely over the years and some members with a history as vaccine critics. Read the AMA's full letter below: Read the AMA's full letter below:Melissa Quinn contributed to this report.
Yahoo
33 minutes ago
- Yahoo
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on


New York Times
36 minutes ago
- New York Times
Judge Indefinitely Blocks Withholding of Medicaid Funds to Planned Parenthood
A federal judge on Monday indefinitely blocked the Trump administration from enforcing a policy that would prevent many Planned Parenthood clinics from receiving federal Medicaid reimbursements if they continue to offer abortion services. The order, issued by Judge Indira Talwani in Federal District Court in Massachusetts, extended a temporary block she had placed on the government earlier this month. She found that the policy retaliated against Planned Parenthood in violation of its First Amendment rights and could amount to an unconstitutional 'legislative punishment.' The lawsuit, filed earlier this month, came in response to a provision introduced in the sprawling policy bill that President Trump signed into law early this month. The bill imposed a one-year ban on state Medicaid payments to any health care nonprofit that offers abortions and received more than $800,000 in Medicaid funding in 2023. Many clinics affiliated with Planned Parenthood, which provide a range of services unrelated to abortion, immediately faced a choice between altering their operations and retaining millions of dollars in funding, or facing a potentially catastrophic loss of revenue. Because almost no other nonprofits or national networks meet the $800,000 threshold set in the bill, Judge Talwani found it was 'easily ascertainable' that the provision was targeted and intended to force Planned Parenthood's hand. Federal law already prohibits the use of federal Medicaid funds for paying for abortions, and Judge Talwani previously found that the provision was designed to indirectly squeeze clinics into dropping such services, using Medicaid payments as leverage. She noted the expansive role that Planned Parenthood's umbrella organization plays in political organizing, saying that the provision could also threaten 'expressive' activity including advocating before Congress, supporting candidates and communicating with voters. In withholding funding from the independent clinics that make up the organization's network, Judge Talwani wrote that the provision effectively held the potential to minimize the organization's footprint across the country. In many states, it could force clinics to vastly reduce services or close. She added that the disruption of the many other health services provided by Planned Parenthood affiliates, including family planning and tests for sexually transmitted infections, generally justified barring the policy from taking effect. The Trump administration last week filed an appeal of the restraining order Judge Talwani issued earlier this month. But pending any action from the court of appeals, the injunction she granted on Monday will stay in effect for the time being. In a broader sense, Judge Talwani also found that the law created unreasonable pressure on individual clinics — including some that may not offer abortion services — simply because of their association with the larger Planned Parenthood network. The provision of the bill, she wrote, 'requires each member to disaffiliate with Planned Parenthood Federation and stop providing abortion to continue participating in Medicaid programs.' Imposing the choice on the federation's members, she added, 'kneecaps the entire organization.'